{"id":"NCT03689946","sponsor":"Cedars-Sinai Medical Center","briefTitle":"Effect of Evolocumab on Coronary Atherosclerosis","officialTitle":"Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by Coronary CTA (CCTA) and Microcalcification by F18-NaF PET: A Phase 3 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-19","primaryCompletion":"2023-01-28","completion":"2023-05-30","firstPosted":"2018-10-01","resultsPosted":"2024-07-17","lastUpdate":"2024-07-17"},"enrollment":55,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cardiovascular Disease","Hyperlipidemia"],"interventions":[{"type":"DRUG","name":"Evolocumab","otherNames":["RepathaÂ®","PCSK9 inhibitor"]},{"type":"DIAGNOSTIC_TEST","name":"18F-NaF PET","otherNames":["18F sodium fluoride","sodium fluoride PET"]},{"type":"DIAGNOSTIC_TEST","name":"CCTA","otherNames":["Coronary computed tomography angiography"]},{"type":"DRUG","name":"Omnipaque","otherNames":["contrast"]},{"type":"DRUG","name":"Metoprolol","otherNames":["beta blocker"]},{"type":"DRUG","name":"Nitroglycerin","otherNames":["vasodilator"]}],"arms":[{"label":"Evolocumab, F18-NaF PET, CCTA","type":"EXPERIMENTAL"}],"summary":"This study will quantify changes in coronary plaque volumes and plaque composition in patients treated with evolocumab.\n\nPrevious intravascular ultrasound studies have shown that treatment with a lipid-lowering PCSK9 enzyme inhibitor, such as evolocumab, to be associated with a reduction of the fatty deposits that cause plaque in the arteries, however, it is not known how evolocumab affects specific coronary plaque types and plaque inflammation.\n\nInvestigators will use quantitative assessment of non-invasive coronary computed tomography angiography (CCTA) and positron emission tomography (PET)imaging to evaluate functional changes in plaque burden, plaque composition and vascular inflammation before and after treatment with evolocumab.\n\nInvestigators propose to show that patients treated with evolocumab in combination with statins demonstrate a greater reduction of coronary non-calcified plaque volume, thereby reducing the number of future cardiac events.","primaryOutcome":{"measure":"Change in Noncalcified Coronary Artery Plaque Volume (NCPV)","timeFrame":"baseline (pre-treatment) and 18 months after of treatment","effectByArm":[{"arm":"Evolocumab, F18-NaF PET, CCTA","deltaMin":-45,"sd":64}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":12},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["40178463"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":55},"commonTop":["runny nose"]}}